{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:32Z","timestamp":1792131032216,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH NRSA","award":["T32CA190216"],"award-info":[{"award-number":["T32CA190216"]}]},{"name":"Training Program in Cancer Biology","award":["1R01CA222299"],"award-info":[{"award-number":["1R01CA222299"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.semcancer.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T02:26:23Z","timestamp":1579919183000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Molecular therapeutics for anaplastic thyroid cancer"],"prefix":"10.1016","volume":"61","author":[{"given":"Nikita","family":"Pozdeyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison M.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Schweppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semcancer.2020.01.005_bib0005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archotol.1988.01860130044012","article-title":"Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer","volume":"114","author":"Spires","year":"1988","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00000658-200003000-00005","article-title":"Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21","volume":"231","author":"Lam","year":"2000","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research, N","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.semcancer.2020.01.005_bib0025","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/annonc\/mdy123","article-title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","volume":"29","author":"Capdevila","year":"2018","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2020.01.005_bib0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/gcc.22678","article-title":"Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor","volume":"57","author":"Dong","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2020.01.005_bib0035","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/modpathol.2017.75","article-title":"Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation","volume":"30","author":"Oishi","year":"2017","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/jc.2007-1076","article-title":"Phosphatidylinositol 3-kinase\/akt and ras\/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer","volume":"93","author":"Santarpia","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1172\/JCI116168","article-title":"High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas","volume":"91","author":"Fagin","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"22","key":"10.1016\/j.semcancer.2020.01.005_bib0050","doi-asserted-by":"crossref","first-page":"10199","DOI":"10.1158\/0008-5472.CAN-04-4259","article-title":"Mutation of the PIK3CA gene in anaplastic thyroid cancer","volume":"65","author":"Garcia-Rostan","year":"2005","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2020.01.005_bib0055","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/j.1349-7006.1992.tb02761.x","article-title":"p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas","volume":"83","author":"Nakamura","year":"1992","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.005_bib0060","first-page":"119","article-title":"Mouse models of follicular and papillary thyroid cancer progression","volume":"2","author":"Russo","year":"2011","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"16","key":"10.1016\/j.semcancer.2020.01.005_bib0065","doi-asserted-by":"crossref","first-page":"E1600","DOI":"10.1073\/pnas.1404357111","article-title":"p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer","volume":"111","author":"McFadden","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.semcancer.2020.01.005_bib0070","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1158\/1541-7786.MCR-14-0158-T","article-title":"Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis","volume":"12","author":"Charles","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2020.01.005_bib0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.18632\/oncotarget.380","article-title":"Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors","volume":"2","author":"Antico Arciuch","year":"2011","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.semcancer.2020.01.005_bib0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0002-9440(10)64577-4","article-title":"Loss of p53 promotes anaplasia and local invasion in ret\/PTC1-induced thyroid carcinomas","volume":"157","author":"La Perle","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0085","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"13","key":"10.1016\/j.semcancer.2020.01.005_bib0090","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2020.01.005_bib0095","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/thy.2015.0506","article-title":"Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAF(V600E) mutation-prevalent area","volume":"26","author":"Jeon","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.semcancer.2020.01.005_bib0100","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","volume":"24","author":"Kunstman","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.semcancer.2020.01.005_bib0105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/thy.2019.0088","article-title":"Short review: genomic alterations in hurthle cell carcinoma","volume":"29","author":"Ganly","year":"2019","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.semcancer.2020.01.005_bib0110","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","article-title":"Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies","volume":"25","author":"Landa","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0115","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/cancers11030402","article-title":"Identification of targetable lesions in anaplastic thyroid cancer by genome profiling","volume":"11","author":"Ravi","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1897-4287-6-1-15","article-title":"Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum","volume":"6","author":"Stulp","year":"2008","journal-title":"Hered. Cancer Clin. Pract."},{"issue":"Suppl","key":"10.1016\/j.semcancer.2020.01.005_bib0130","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.semcancer.2020.01.005_bib0135","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.semcancer.2020.01.005_bib0140","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2020.01.005_bib0145","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.semcancer.2020.01.005_bib0150","first-page":"1811","article-title":"Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma","volume":"59","author":"Garcia-Rostan","year":"1999","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2020.01.005_bib0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1530\/EJE-18-0653","article-title":"Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma","volume":"180","author":"van der Tuin","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.semcancer.2020.01.005_bib0160","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/thy.2016.0254","article-title":"Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases","volume":"27","author":"Bonhomme","year":"2017","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.semcancer.2020.01.005_bib0165","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.semcancer.2020.01.005_bib0170","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1172\/JCI115743","article-title":"Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype","volume":"89","author":"Santoro","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.semcancer.2020.01.005_bib0175","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/thy.2017.0285","article-title":"Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.semcancer.2020.01.005_bib0190","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","article-title":"Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid","volume":"23","author":"Savvides","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.semcancer.2020.01.005_bib0195","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejca.2017.01.029","article-title":"A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study","volume":"76","author":"Ravaud","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2020.01.005_bib0200","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer","volume":"97","author":"Bible","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2020.01.005_bib0205","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-014-2604-8","article-title":"A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic\/pharmacodynamic analyses","volume":"74","author":"Cohen","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.semcancer.2020.01.005_bib0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000485972","article-title":"Lenvatinib for anaplastic thyroid cancer and lenvatinib-induced thyroid dysfunction","volume":"7","author":"Koyama","year":"2018","journal-title":"Eur. Thyroid J."},{"issue":"10","key":"10.1016\/j.semcancer.2020.01.005_bib0220","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","article-title":"Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer","volume":"22","author":"Kollipara","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.semcancer.2020.01.005_bib0225","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/thy.2018.0060","article-title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma","volume":"28","author":"Cabanillas","year":"2018","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0230","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2020.01.005_bib0235","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1172\/JCI120966","article-title":"Hgf\/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers","volume":"128","author":"Knauf","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.semcancer.2020.01.005_bib0240","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.celrep.2014.07.010","article-title":"Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors","volume":"8","author":"Sos","year":"2014","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.semcancer.2020.01.005_bib0245","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2020.01.005_bib0250","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1038\/cddis.2014.78","article-title":"Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K\/AKT pathways","volume":"5","author":"Gunda","year":"2014","journal-title":"Cell Death Dis."},{"issue":"7387","key":"10.1016\/j.semcancer.2020.01.005_bib0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.semcancer.2020.01.005_bib0260","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1158\/1078-0432.CCR-11-0933","article-title":"Synergistic action of a RAF inhibitor and a dual PI3K\/mTOR inhibitor in thyroid cancer","volume":"17","author":"Jin","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.semcancer.2020.01.005_bib0265","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.18632\/oncotarget.9023","article-title":"Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model","volume":"7","author":"Danysh","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.semcancer.2020.01.005_bib0270","first-page":"409","article-title":"KRAS G12V mutation in acquired resistance to combined BRAF and MEK inhibition in papillary thyroid Cancer","volume":"17","author":"Owen","year":"2019","journal-title":"J. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0275","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.semcancer.2020.01.005_bib0280","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","article-title":"The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF","volume":"74","author":"Watson","year":"2014","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2020.01.005_bib0285","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical acquired resistance to RAF inhibitor combinations in BRAF-Mutant colorectal Cancer through MAPK pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.semcancer.2020.01.005_bib0290","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/jid.2012.63","article-title":"Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF\/MEK inhibition","volume":"132","author":"Gowrishankar","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.01.005_bib0295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","article-title":"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.semcancer.2020.01.005_bib0300","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.semcancer.2020.01.005_bib0305","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1172\/JCI89067","article-title":"Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine","volume":"126","author":"Nagarajah","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.semcancer.2020.01.005_bib0310","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1158\/2159-8290.CD-17-1355","article-title":"ERK Inhibition: a new front in the war against MAPK pathway-driven cancers?","volume":"8","author":"Smalley","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.semcancer.2020.01.005_bib0315","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","article-title":"Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1\/2 inhibitor BVD-523 (Ulixertinib)","volume":"16","author":"Germann","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2020.01.005_bib0320","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","article-title":"Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors","volume":"3","author":"Morris","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.semcancer.2020.01.005_bib0325","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.semcancer.2020.01.005_bib0330","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/1535-7163.MCT-15-0702","article-title":"The mitogen-activated protein kinase pathway facilitates resistance to the src inhibitor dasatinib in thyroid cancer","volume":"15","author":"Beadnell","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.semcancer.2020.01.005_bib0335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41389-017-0015-5","article-title":"Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer","volume":"7","author":"Beadnell","year":"2018","journal-title":"Oncogenesis"},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0340","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hed.23316","article-title":"Src inhibitors in suppression of papillary thyroid carcinoma growth","volume":"36","author":"Henderson","year":"2014","journal-title":"Head Neck"},{"issue":"9","key":"10.1016\/j.semcancer.2020.01.005_bib0345","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/ERC-19-0107","article-title":"Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer","volume":"26","author":"Zhu","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"6330","key":"10.1016\/j.semcancer.2020.01.005_bib0350","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.semcancer.2020.01.005_bib0355","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.semcancer.2020.01.005_bib0360","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","article-title":"Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers","volume":"78","author":"Untch","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.01.005_bib0365","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2017.12.037","article-title":"A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer","volume":"417","author":"Lee","year":"2018","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0370","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 inhibitors in breast cancer: current controversies and future directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 inhibitors in breast cancer: current controversies and future directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.semcancer.2020.01.005_bib0380","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/ERC-19-0011","article-title":"PI3K\/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2020.01.005_bib0385","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ijc.26057","article-title":"Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo","volume":"130","author":"Catalano","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.semcancer.2020.01.005_bib0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077684","article-title":"Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.semcancer.2020.01.005_bib0395","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","article-title":"APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity","volume":"5","author":"Swanton","year":"2015","journal-title":"Cancer Discov."},{"issue":"7463","key":"10.1016\/j.semcancer.2020.01.005_bib0400","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.semcancer.2020.01.005_bib0405","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-16-3389","article-title":"APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition","volume":"77","author":"Buisson","year":"2017","journal-title":"Cancer Res."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20300067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20300067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:37:15Z","timestamp":1760917035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X20300067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":81,"alternative-id":["S1044579X20300067"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.01.005","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular therapeutics for anaplastic thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}